Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 15 versus EVEKEO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 15 versus EVEKEO.
ADDERALL XR 15 vs EVEKEO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADDERALL XR contains a mixture of amphetamine salts, including dextroamphetamine and levoamphetamine. The mechanism of action involves increasing synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic terminals, leading to CNS stimulation.
EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.
Oral, 20-60 mg once daily in the morning; initial dose 20 mg once daily, titrated by 10-20 mg weekly based on tolerability and efficacy.
5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.
None Documented
None Documented
The terminal elimination half-life of amphetamine in adults is approximately 10-13 hours; in children, it is slightly shorter (6-8 hours). For the l-amphetamine isomer, the half-life is 9-11 hours. The extended-release formulation provides a prolonged duration of effect due to a biphasic release profile.
Terminal elimination half-life: 2-3 hours. Clinical context: Short half-life supports multiple daily dosing for seizure control. May be prolonged in hepatic impairment.
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites including deaminated and oxidized products; fecal excretion accounts for less than 10%.
Renal: 30-50% as unchanged drug; fecal: 50-70% as metabolites and unchanged drug.
Category C
Category C
CNS Stimulant
CNS Stimulant